Chiusura precedente | 115,19 |
Aperto | 113,24 |
Denaro | N/D x N/D |
Lettera | N/D x N/D |
Min-Max giorno | 112,38 - 114,02 |
Intervallo di 52 settimane | 90,70 - 120,00 |
Volume | |
Media Volume | 1.136.489 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 0,36 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) ............. Changes in the Executive Board of Nestlé S.A. Vevey, September 22, 2023 After nine years as Chief Executive Officer of Nestlé Health Science, Greg Behar will leave Nestlé as of December 31, 2023, to pursue new professional interests outside the company. Greg Behar helped establish Nestlé Health Science as a leader in nutritional health solutions, growing the company
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) ............. Vevey, September 4, 2023 Nestlé divests its Palforzia business Nestlé announced today that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing. This agreement follows Nestlé's announcement last year t
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live 14:00 CEST Investor call audio webcast Full details in Events Report published today Half-Year Report (pdf) Other language versions available in Publications ............. Vevey, July 27, 2023 Nestlé reports half-year results for 2023 Organic growth reached 8.7%, with pricing of 9.5% and real internal growth (RIG) of - 0.8%. Growth was broad-based across